{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T05:23:18Z","timestamp":1792473798858,"version":"4.5.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,17]],"date-time":"2024-11-17T00:00:00Z","timestamp":1731801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,17]],"date-time":"2024-11-17T00:00:00Z","timestamp":1731801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201800013C"],"award-info":[{"award-number":["HHSN272201800013C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201800013C"],"award-info":[{"award-number":["HHSN272201800013C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201800013C"],"award-info":[{"award-number":["HHSN272201800013C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201800013C"],"award-info":[{"award-number":["HHSN272201800013C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201800013C"],"award-info":[{"award-number":["HHSN272201800013C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201800013C"],"award-info":[{"award-number":["HHSN272201800013C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201800013C"],"award-info":[{"award-number":["HHSN272201800013C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201800013C"],"award-info":[{"award-number":["HHSN272201800013C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201800013C"],"award-info":[{"award-number":["HHSN272201800013C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201800013C"],"award-info":[{"award-number":["HHSN272201800013C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201800013C"],"award-info":[{"award-number":["HHSN272201800013C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201800013C"],"award-info":[{"award-number":["HHSN272201800013C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201800013C"],"award-info":[{"award-number":["HHSN272201800013C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201800013C"],"award-info":[{"award-number":["HHSN272201800013C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011541","name":"U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute","doi-asserted-by":"publisher","award":["75N91019D00024"],"award-info":[{"award-number":["75N91019D00024"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21AI121840"],"award-info":[{"award-number":["R21AI121840"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21AI169789"],"award-info":[{"award-number":["R21AI169789"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Lassa virus (LASV) is a rodent-borne mammarenavirus that causes tens to hundreds of thousands of human infections annually in Western Africa. Approximately 20% of these infections progress to Lassa fever (LF), an acute disease with case\u2013fatality rates from \u224820\u201370%. Currently, there are no approved vaccines or specific therapeutics to prevent or treat LF. The LASV genome consists of a small (S) segment that has two genes, <jats:italic>GP<\/jats:italic> and <jats:italic>NP<\/jats:italic>, and a large (L) segment that has two genes, <jats:italic>L<\/jats:italic> and <jats:italic>Z<\/jats:italic>. In both segments, the two genes are separated by non-coding intergenic regions (IGRs). Recombinant LASVs (rLASVs), in which the L segment IGR was replaced with the S segment IGR or in which the <jats:italic>GP<\/jats:italic> gene was codon-deoptimized, lost fitness in vitro, were highly attenuated in vivo, and, when used as vaccines, protected domesticated guinea pigs from otherwise lethal LASV exposure. Here, we report the generation of rLASV\/IGR-CD, which includes both determinants of attenuation and further enhances the safety of the vaccine compared with its predecessors. rLASV\/IGR-CD grew to high titers in Vero cells, which are approved for human vaccine production, but did not cause signs of disease or pathology in guinea pigs. Importantly, guinea pigs vaccinated with rLASV\/IGR-CD were completely protected from disease and death after a typically lethal exposure to wild-type LASV. Our data support the development of rLASV\/IGR-CD as a live-attenuated LF vaccine with stringent safety features.<\/jats:p>","DOI":"10.1038\/s41541-024-01012-w","type":"journal-article","created":{"date-parts":[[2024,11,17]],"date-time":"2024-11-17T04:58:35Z","timestamp":1731819515000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A Lassa virus live attenuated vaccine candidate that is safe and efficacious in guinea pigs"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5493-3880","authenticated-orcid":false,"given":"Brian D.","family":"Carey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuiqing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian","family":"Geiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1934-9494","authenticated-orcid":false,"given":"Chengjin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis M.","family":"Huzella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca J.","family":"Reeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3928-3733","authenticated-orcid":false,"given":"Monika","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Bernbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Cubitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1949-973X","authenticated-orcid":false,"given":"Bapi","family":"Pahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1590-7401","authenticated-orcid":false,"given":"Scott M.","family":"Anthony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8135-9976","authenticated-orcid":false,"given":"Anthony","family":"Marketon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"Bernbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie P.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Crozier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7084-0804","authenticated-orcid":false,"given":"Luis","family":"Mart\u00ednez-Sobrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7485-2204","authenticated-orcid":false,"given":"Gabriella","family":"Worwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8171-8115","authenticated-orcid":false,"given":"Juan Carlos","family":"de la Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7800-6045","authenticated-orcid":false,"given":"Jens H.","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,17]]},"reference":[{"key":"1012_CR1","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/227174a0","volume":"227","author":"SM Buckley","year":"1970","unstructured":"Buckley, S. M., Casals, J. & Downs, W. G. Isolation and antigenic characterization of Lassa virus. Nature 227, 174 (1970).","journal-title":"Nature"},{"key":"1012_CR2","doi-asserted-by":"publisher","first-page":"001891","DOI":"10.1099\/jgv.0.001891","volume":"104","author":"SR Radoshitzky","year":"2023","unstructured":"Radoshitzky, S. R. et al. ICTV virus taxonomy profile: Arenaviridae 2023. J Gen Virol 104, 001891 (2023).","journal-title":"J Gen Virol"},{"key":"1012_CR3","unstructured":"World Health Organization. R&D Blueprint. Lassa fever. https:\/\/www.who.int\/teams\/blueprint\/lassa-fever (2018)."},{"key":"1012_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1126\/science.185.4147.263","volume":"185","author":"TP Monath","year":"1974","unstructured":"Monath, T. P., Newhouse, V. F., Kemp, G. E., Setzer, H. W. & Cacciapuoti, A. Lassa virus isolation from Mastomys natalensis rodents during an epidemic in Sierra Leone. Science 185, 263\u2013265 (1974).","journal-title":"Science"},{"key":"1012_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/srep25280","volume":"6","author":"A Olayemi","year":"2016","unstructured":"Olayemi, A. et al. New hosts of the Lassa virus. Sci Rep 6, 25280 (2016).","journal-title":"Sci Rep"},{"key":"1012_CR6","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.3201\/eid2510.180523","volume":"25","author":"A Yadouleton","year":"2019","unstructured":"Yadouleton, A. et al. Lassa virus in pygmy mice, Benin, 2016-2017. Emerg Infect Dis 25, 1977\u20131979 (2019).","journal-title":"Emerg Infect Dis"},{"key":"1012_CR7","first-page":"67","volume":"440","author":"AR Smither","year":"2023","unstructured":"Smither, A. R. & Bell-Kareem, A. R. Ecology of Lassa virus. Curr Top Microbiol Immunol 440, 67\u201386 (2023).","journal-title":"Curr Top Microbiol Immunol"},{"key":"1012_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41579-022-00789-8","volume":"21","author":"RF Garry","year":"2023","unstructured":"Garry, R. F. Lassa fever - the road ahead. Nat Rev Microbiol 21, 87\u201396 (2023).","journal-title":"Nat Rev Microbiol"},{"key":"1012_CR9","doi-asserted-by":"publisher","first-page":"20180268","DOI":"10.1098\/rstb.2018.0268","volume":"374","author":"AR Akhmetzhanov","year":"2019","unstructured":"Akhmetzhanov, A. R., Asai, Y. & Nishiura, H. Quantifying the seasonal drivers of transmission for Lassa fever in Nigeria. Philos Trans R Soc Lond B Biol Sci 374, 20180268 (2019).","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"1012_CR10","doi-asserted-by":"publisher","first-page":"935","DOI":"10.4269\/ajtmh.16-0675","volume":"96","author":"J Bonwitt","year":"2017","unstructured":"Bonwitt, J. et al. At home with Mastomys and Rattus: human-rodent interactions and potential for primary transmission of Lassa virus in domestic spaces. Am J Trop Med Hyg 96, 935\u2013943 (2017).","journal-title":"Am J Trop Med Hyg"},{"key":"1012_CR11","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jhin.2003.08.002","volume":"55","author":"CM Swaan","year":"2003","unstructured":"Swaan, C. M. et al. Management of a patient with Lassa fever to prevent transmission. J Hosp Infect 55, 234\u2013235 (2003).","journal-title":"J Hosp Infect"},{"key":"1012_CR12","doi-asserted-by":"publisher","first-page":"661","DOI":"10.4269\/ajtmh.1996.55.661","volume":"55","author":"M Ter","year":"1996","unstructured":"Ter, M. et al. Hunting of peridomestic rodents and consumption of their meat as possible risk factors for rodent-to-human transmission of Lassa virus in the Republic of Guinea. Am J Trop Med Hyg 55, 661\u2013666 (1996).","journal-title":"Am J Trop Med Hyg"},{"key":"1012_CR13","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1093\/inthealth\/ihac076","volume":"15","author":"D Simons","year":"2023","unstructured":"Simons, D. Lassa fever cases suffer from severe underreporting based on reported fatalities. Int Health 15, 608\u2013610 (2023).","journal-title":"Int Health"},{"key":"1012_CR14","doi-asserted-by":"publisher","first-page":"e0010938","DOI":"10.1371\/journal.pntd.0010938","volume":"17","author":"DS Grant","year":"2023","unstructured":"Grant, D. S. et al. Seroprevalence of anti-Lassa Virus IgG antibodies in three districts of Sierra Leone: a cross-sectional, population-based study. PLoS Negl Trop Dis 17, e0010938 (2023).","journal-title":"PLoS Negl Trop Dis"},{"key":"1012_CR15","first-page":"165","volume":"440","author":"DS Grant","year":"2023","unstructured":"Grant, D. S., Samuels, R. J., Garry, R. F. & Schieffelin, J. S. Lassa fever natural history and clinical management. Curr Top Microbiol Immunol 440, 165\u2013192 (2023).","journal-title":"Curr Top Microbiol Immunol"},{"key":"1012_CR16","doi-asserted-by":"publisher","first-page":"262","DOI":"10.2105\/AJPH.2017.304186","volume":"108","author":"MI Buba","year":"2018","unstructured":"Buba, M. I. et al. Mortality among confirmed Lassa fever cases during the 2015-2016 outbreak in Nigeria. Am J Public Health 108, 262\u2013264 (2018).","journal-title":"Am J Public Health"},{"key":"1012_CR17","doi-asserted-by":"publisher","first-page":"e2748","DOI":"10.1371\/journal.pntd.0002748","volume":"8","author":"JG Shaffer","year":"2014","unstructured":"Shaffer, J. G. et al. Lassa fever in post-conflict Sierra Leone. PLoS Negl Trop Dis 8, e2748 (2014).","journal-title":"PLoS Negl Trop Dis"},{"key":"1012_CR18","doi-asserted-by":"publisher","first-page":"e0009576","DOI":"10.1371\/journal.pntd.0009576","volume":"15","author":"MR Koch","year":"2021","unstructured":"Koch, M. R. et al. Health seeking behavior after the 2013-16 Ebola epidemic: Lassa fever as a metric of persistent changes in Kenema District, Sierra Leone. PLoS Negl Trop Dis 15, e0009576 (2021).","journal-title":"PLoS Negl Trop Dis"},{"key":"1012_CR19","doi-asserted-by":"publisher","first-page":"e0214284","DOI":"10.1371\/journal.pone.0214284","volume":"14","author":"JG Shaffer","year":"2019","unstructured":"Shaffer, J. G. et al. A medical records and data capture and management system for Lassa fever in Sierra Leone: approach, implementation, and challenges. PLoS One 14, e0214284 (2019).","journal-title":"PLoS One"},{"key":"1012_CR20","doi-asserted-by":"publisher","first-page":"103673","DOI":"10.1016\/j.dib.2019.01.021","volume":"23","author":"JG Shaffer","year":"2019","unstructured":"Shaffer, J. G. et al. Data set on Lassa fever in post-conflict Sierra Leone. Data Brief 23, 103673 (2019).","journal-title":"Data Brief"},{"key":"1012_CR21","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3390\/microorganisms9030586","volume":"9","author":"JG Shaffer","year":"2021","unstructured":"Shaffer, J. G. et al. Space-time trends in Lassa fever in Sierra Leone by ELISA serostatus, 2012-2019. Microorganisms 9, 586 (2021).","journal-title":"Microorganisms"},{"key":"1012_CR22","doi-asserted-by":"publisher","first-page":"670","DOI":"10.4269\/ajtmh.1970.19.670","volume":"19","author":"JD Frame","year":"1970","unstructured":"Frame, J. D., Baldwin, J. M. Jr., Gocke, D. J. & Troup, J. M. Lassa fever, a new virus disease of man from West Africa. I. clinical description and pathological findings. Am J Trop Med Hyg 19, 670\u2013676 (1970).","journal-title":"Am J Trop Med Hyg"},{"key":"1012_CR23","first-page":"389","volume":"31","author":"J Knobloch","year":"1980","unstructured":"Knobloch, J. et al. Clinical observations in 42 patients with Lassa fever. Tropenmed Parasitol 31, 389\u2013398 (1980).","journal-title":"Tropenmed Parasitol"},{"key":"1012_CR24","doi-asserted-by":"publisher","first-page":"408","DOI":"10.4269\/ajtmh.1987.36.408","volume":"36","author":"MH Monson","year":"1987","unstructured":"Monson, M. H. et al. Pediatric Lassa fever: a review of 33 Liberian cases. Am J Trop Med Hyg 36, 408\u2013415 (1987).","journal-title":"Am J Trop Med Hyg"},{"key":"1012_CR25","doi-asserted-by":"crossref","unstructured":"Frame, J. D. Clinical features of Lassa fever in Liberia. Rev Infect Dis 11, S783\u2013S789 (1989).","DOI":"10.1093\/clinids\/11.Supplement_4.S783"},{"key":"1012_CR26","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1001\/jama.1990.03450160063030","volume":"264","author":"D Cummins","year":"1990","unstructured":"Cummins, D. et al. Acute sensorineural deafness in Lassa fever. Jama 264, 2093\u20132096 (1990).","journal-title":"Jama"},{"key":"1012_CR27","first-page":"197","volume":"95","author":"D Cummins","year":"1992","unstructured":"Cummins, D. et al. Lassa fever encephalopathy: clinical and laboratory findings. J Trop Med Hyg 95, 197\u2013201 (1992).","journal-title":"J Trop Med Hyg"},{"key":"1012_CR28","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/0166-3542(92)90073-E","volume":"19","author":"SP Fisher-Hoch","year":"1992","unstructured":"Fisher-Hoch, S. P., Gborie, S., Parker, L. & Huggins, J. Unexpected adverse reactions during a clinical trial in rural west Africa. Antiviral Res 19, 139\u2013147 (1992).","journal-title":"Antiviral Res"},{"key":"1012_CR29","doi-asserted-by":"publisher","first-page":"e841","DOI":"10.1093\/cid\/ciac578","volume":"76","author":"M Groger","year":"2023","unstructured":"Groger, M. et al. Pharmacokinetics of ribavirin in the treatment of Lassa fever: an observational clinical study at the Irrua Specialist Teaching Hospital, Edo State, Nigeria. Clin Infect Dis 76, e841\u2013e848 (2023).","journal-title":"Clin Infect Dis"},{"key":"1012_CR30","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.3201\/eid2810.220625","volume":"28","author":"S Okogbenin","year":"2022","unstructured":"Okogbenin, S. et al. Two cases of Lassa fever successfully treated with ribavirin and adjunct dexamethasone for concomitant infections. Emerg Infect Dis 28, 2060\u20132063 (2022).","journal-title":"Emerg Infect Dis"},{"key":"1012_CR31","doi-asserted-by":"publisher","first-page":"e0009522","DOI":"10.1371\/journal.pntd.0009522","volume":"15","author":"AP Salam","year":"2021","unstructured":"Salam, A. P. et al. Time to reconsider the role of ribavirin in Lassa fever. PLoS Negl Trop Dis 15, e0009522 (2021).","journal-title":"PLoS Negl Trop Dis"},{"key":"1012_CR32","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJM198601023140104","volume":"314","author":"JB McCormick","year":"1986","unstructured":"McCormick, J. B. et al. Lassa fever. Effective therapy with ribavirin. N Engl J Med 314, 20\u201326 (1986).","journal-title":"N Engl J Med"},{"key":"1012_CR33","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.3201\/eid2808.211787","volume":"28","author":"H-Y Cheng","year":"2022","unstructured":"Cheng, H.-Y. et al. Lack of evidence for ribavirin treatment of Lassa fever in systematic review of published and unpublished studies. Emerg Infect Dis 28, 1559\u20131568 (2022).","journal-title":"Emerg Infect Dis"},{"key":"1012_CR34","doi-asserted-by":"crossref","unstructured":"Nu\u00f1ez, I. A., Crane, A., Crozier, I., Worwa, G. & Kuhn, J. H. Treatment of highly virulent mammarenavirus infections\u2014status quo and future directions. Expert Opin Drug Discov 19, 537\u2013551 (2024).","DOI":"10.1080\/17460441.2024.2340494"},{"key":"1012_CR35","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/14760584.2023.2290683","volume":"23","author":"H Ly","year":"2024","unstructured":"Ly, H. Progress toward the development of Lassa vaccines. Expert Rev Vaccines 23, 5\u20137 (2024).","journal-title":"Expert Rev Vaccines"},{"key":"1012_CR36","unstructured":"Radoshitzky, S. R., Buchmeier, M. J. & de la Torre, J. C. in Fields Virology Vol. 1 (Emerging Viruses) (eds Peter M. Howley, David M. Knipe, & Sean P. J. Whelan) Ch. 18, 784-809 (Wolters Kluwer\/Lippincott Williams & Wilkins, 2020)."},{"key":"1012_CR37","doi-asserted-by":"publisher","first-page":"11330","DOI":"10.1128\/JVI.00763-09","volume":"83","author":"L Mart\u00ednez-Sobrido","year":"2009","unstructured":"Mart\u00ednez-Sobrido, L. et al. Identification of amino acid residues critical for the anti-interferon activity of the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol 83, 11330\u201311340 (2009).","journal-title":"J Virol"},{"key":"1012_CR38","doi-asserted-by":"publisher","first-page":"12696","DOI":"10.1128\/JVI.00882-07","volume":"81","author":"L Marti\u0301nez-Sobrido","year":"2007","unstructured":"Marti\u0301nez-Sobrido, L., Giannakas, P., Cubitt, B., Garci\u0301a-Sastre, A. & de la Torre, J. C. Differential inhibition of type I interferon induction by arenavirus nucleoproteins. J Virol 81, 12696\u201312703 (2007).","journal-title":"J Virol"},{"key":"1012_CR39","doi-asserted-by":"publisher","first-page":"9192","DOI":"10.1128\/JVI.00555-06","volume":"80","author":"L Marti\u0301nez-Sobrido","year":"2006","unstructured":"Marti\u0301nez-Sobrido, L., Zu\u0301n\u0303iga, E. I., Rosario, D., Garci\u0301a-Sastre, A. & de la Torre, J. C. Inhibition of the type I interferon response by the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol 80, 9192\u20139199 (2006).","journal-title":"J Virol"},{"key":"1012_CR40","doi-asserted-by":"publisher","first-page":"7270","DOI":"10.1128\/jvi.66.12.7270-7281.1992","volume":"66","author":"P Borrow","year":"1992","unstructured":"Borrow, P. & Oldstone, M. B. Characterization of lymphocytic choriomeningitis virus-binding protein(s): a candidate cellular receptor for the virus. J Virol 66, 7270\u20137281 (1992).","journal-title":"J Virol"},{"key":"1012_CR41","doi-asserted-by":"publisher","first-page":"7677","DOI":"10.1128\/JVI.00560-08","volume":"82","author":"JM Rojek","year":"2008","unstructured":"Rojek, J. M., Sanchez, A. B., Nguyen, N. T., de la Torre, J. C. & Kunz, S. Different mechanisms of cell entry by human-pathogenic Old World and New World arenaviruses. J Virol 82, 7677\u20137687 (2008).","journal-title":"J Virol"},{"key":"1012_CR42","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.3390\/v4102162","volume":"4","author":"DJ Burri","year":"2012","unstructured":"Burri, D. J., da Palma, J. R., Kunz, S. & Pasquato, A. Envelope glycoprotein of arenaviruses. Viruses 4, 2162\u20132181 (2012).","journal-title":"Viruses"},{"key":"1012_CR43","doi-asserted-by":"crossref","unstructured":"Cai, Y. et al. A Lassa virus live-attenuated vaccine candidate based on rearrangement of the intergenic region. mBio 11, e00186\u201300120 (2020).","DOI":"10.1128\/mBio.00186-20"},{"key":"1012_CR44","doi-asserted-by":"crossref","unstructured":"Cai, Y. et al. A Lassa fever live-attenuated vaccine based on codon deoptimization of the viral glycoprotein gene. mBio 11, e00039\u201300020 (2020).","DOI":"10.1128\/mBio.00039-20"},{"key":"1012_CR45","doi-asserted-by":"publisher","first-page":"e0138522","DOI":"10.1128\/jvi.01385-22","volume":"97","author":"S Sakabe","year":"2023","unstructured":"Sakabe, S., Cubitt, B., Martinez-Sobrido, L. & de la Torre, J. C. Molecular engineering of a mammarenavirus with unbreachable attenuation. J Virol 97, e0138522 (2023).","journal-title":"J Virol"},{"key":"1012_CR46","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1128\/iai.37.2.771-778.1982","volume":"37","author":"PB Jahrling","year":"1982","unstructured":"Jahrling, P. B., Smith, S., Hesse, R. A. & Rhoderick, J. B. Pathogenesis of Lassa virus infection in guinea pigs. Infect Immun 37, 771\u2013778 (1982).","journal-title":"Infect Immun"},{"key":"1012_CR47","doi-asserted-by":"publisher","first-page":"e02230","DOI":"10.1128\/JVI.02230-17","volume":"92","author":"X Carnec","year":"2018","unstructured":"Carnec, X. et al. A vaccine platform against arenaviruses based on a recombinant hyperattenuated Mopeia virus expressing heterologous glycoproteins. J Virol 92, e02230\u201302217 (2018).","journal-title":"J Virol"},{"key":"1012_CR48","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1073\/pnas.86.1.317","volume":"86","author":"SP Fisher-Hoch","year":"1989","unstructured":"Fisher-Hoch, S. P. et al. Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene. Proc Natl Acad Sci USA 86, 317\u2013321 (1989).","journal-title":"Proc Natl Acad Sci USA"},{"key":"1012_CR49","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3390\/pathogens8030133","volume":"8","author":"MS Salvato","year":"2019","unstructured":"Salvato, M. S. et al. A single dose of modified vaccinia Ankara expressing Lassa virus-like particles protects mice from lethal intra-cerebral virus challenge. Pathogens 8, 133 (2019).","journal-title":"Pathogens"},{"key":"1012_CR50","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1371\/journal.pmed.0020183","volume":"2","author":"TW Geisbert","year":"2005","unstructured":"Geisbert, T. W. et al. Development of a new vaccine for the prevention of Lassa fever. PLoS Med 2, e183 (2005).","journal-title":"PLoS Med"},{"key":"1012_CR51","doi-asserted-by":"publisher","first-page":"e0003736","DOI":"10.1371\/journal.pntd.0003736","volume":"9","author":"D Safronetz","year":"2015","unstructured":"Safronetz, D. et al. A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses. PLoS Negl Trop Dis 9, e0003736 (2015).","journal-title":"PLoS Negl Trop Dis"},{"key":"1012_CR52","doi-asserted-by":"publisher","first-page":"111094","DOI":"10.1016\/j.celrep.2022.111094","volume":"40","author":"RW Cross","year":"2022","unstructured":"Cross, R. W. et al. A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against heterologous lethal Lassa fever. Cell Rep 40, 111094 (2022).","journal-title":"Cell Rep"},{"key":"1012_CR53","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.virol.2005.12.001","volume":"345","author":"PJ Bredenbeek","year":"2006","unstructured":"Bredenbeek, P. J. et al. A recombinant yellow fever 17D vaccine expressing Lassa virus glycoproteins. Virology 345, 299\u2013304 (2006).","journal-title":"Virology"},{"key":"1012_CR54","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.vaccine.2010.11.079","volume":"29","author":"X Jiang","year":"2011","unstructured":"Jiang, X. et al. Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs. Vaccine 29, 1248\u20131257 (2011).","journal-title":"Vaccine"},{"key":"1012_CR55","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","volume":"395","author":"FC Zhu","year":"2020","unstructured":"Zhu, F. C. et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 395, 1845\u20131854 (2020).","journal-title":"Lancet"},{"key":"1012_CR56","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1310566","volume":"369","author":"SM Hammer","year":"2013","unstructured":"Hammer, S. M. et al. Efficacy trial of a DNA\/rAd5 HIV-1 preventive vaccine. N Engl J Med 369, 2083\u20132092 (2013).","journal-title":"N Engl J Med"},{"key":"1012_CR57","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","volume":"384","author":"NH Schultz","year":"2021","unstructured":"Schultz, N. H. et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med 384, 2124\u20132130 (2021).","journal-title":"N Engl J Med"},{"key":"1012_CR58","doi-asserted-by":"publisher","first-page":"328","DOI":"10.53854\/liim-2903-3","volume":"29","author":"R Vanaparthy","year":"2021","unstructured":"Vanaparthy, R., Mohan, G., Vasireddy, D. & Atluri, P. Review of COVID-19 viral vector-based vaccines and COVID-19 variants. Infez Med 29, 328\u2013338 (2021).","journal-title":"Infez Med"},{"key":"1012_CR59","unstructured":"National Library of Medicine. A clinical trial to evaluate the safety and immunogenicity of rVSV\u2206G-LASV-GPC vaccine in adults in good general heath. https:\/\/clinicaltrials.gov\/study\/NCT04794218. (2024)."},{"key":"1012_CR60","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1128\/JVI.02102-10","volume":"85","author":"SF Emonet","year":"2011","unstructured":"Emonet, S. F. et al. Rescue from cloned cDNAs and in vivo characterization of recombinant pathogenic Romero and live-attenuated Candid #1 strains of Junin virus, the causative agent of Argentine hemorrhagic fever disease. J Virol 85, 1473\u20131483 (2011).","journal-title":"J Virol"},{"key":"1012_CR61","doi-asserted-by":"publisher","first-page":"635","DOI":"10.3390\/vaccines11030635","volume":"11","author":"T Saito","year":"2023","unstructured":"Saito, T. et al. Vaccine candidates against arenavirus Infections. Vaccines (Basel) 11, 635 (2023).","journal-title":"Vaccines (Basel)"},{"key":"1012_CR62","doi-asserted-by":"publisher","first-page":"403","DOI":"10.4269\/ajtmh.1993.48.403","volume":"48","author":"KT McKee Jr.","year":"1993","unstructured":"McKee, K. T. Jr., Oro, J. G., Kuehne, A. I., Spisso, J. A. & Mahlandt, B. G. Safety and immunogenicity of a live-attenuated Junin (Argentine hemorrhagic fever) vaccine in rhesus macaques. Am J Trop Med Hyg 48, 403\u2013411 (1993).","journal-title":"Am J Trop Med Hyg"},{"key":"1012_CR63","first-page":"239","volume":"263","author":"DA Enria","year":"2002","unstructured":"Enria, D. A. & Barrera Oro, J. G. Junin virus vaccines. Curr Top Microbiol Immunol 263, 239\u2013261 (2002).","journal-title":"Curr Top Microbiol Immunol"},{"key":"1012_CR64","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.coviro.2013.04.007","volume":"3","author":"D Falzarano","year":"2013","unstructured":"Falzarano, D. & Feldmann, H. Vaccines for viral hemorrhagic fevers \u2013 progress and shortcomings. Curr Opin Virol 3, 343\u2013351 (2013).","journal-title":"Curr Opin Virol"},{"key":"1012_CR65","doi-asserted-by":"crossref","unstructured":"Plitnick, L. M. in Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics (eds Lisa M. Plitnick & Danuta J. Herzyk) 225-241 (Academic Press, 2013).","DOI":"10.1016\/B978-0-12-394810-6.00009-5"},{"key":"1012_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41426-018-0119-9","volume":"7","author":"J Fernandes","year":"2018","unstructured":"Fernandes, J. et al. Xapuri virus, a novel mammarenavirus: natural reassortment and increased diversity between New World viruses. Emerg Microbes Infect 7, 120 (2018).","journal-title":"Emerg Microbes Infect"},{"key":"1012_CR67","first-page":"133","volume":"2","author":"M Stenglein","year":"2015","unstructured":"Stenglein, M., Jacobson, E. & DeRisi, J. Recombination, reassortment, and many-to-one genotypes in natural arenavirus infections. New Horiz Transl Med 2, 133\u2013134 (2015).","journal-title":"New Horiz Transl Med"},{"key":"1012_CR68","doi-asserted-by":"publisher","first-page":"e1004900","DOI":"10.1371\/journal.ppat.1004900","volume":"11","author":"MD Stenglein","year":"2015","unstructured":"Stenglein, M. D. et al. Widespread recombination, reassortment, and transmission of unbalanced compound viral genotypes in natural arenavirus infections. PLoS Pathog 11, e1004900 (2015).","journal-title":"PLoS Pathog"},{"key":"1012_CR69","doi-asserted-by":"publisher","first-page":"13934","DOI":"10.1128\/JVI.79.22.13934-13942.2005","volume":"79","author":"IS Lukashevich","year":"2005","unstructured":"Lukashevich, I. S. et al. A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. J Virol 79, 13934\u201313942 (2005).","journal-title":"J Virol"},{"key":"1012_CR70","doi-asserted-by":"publisher","first-page":"4093","DOI":"10.1016\/j.vaccine.2007.02.038","volume":"25","author":"R Carrion Jr.","year":"2007","unstructured":"Carrion, R. Jr. et al. A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity. Vaccine 25, 4093\u20134102 (2007).","journal-title":"Vaccine"},{"key":"1012_CR71","doi-asserted-by":"publisher","first-page":"5246","DOI":"10.1016\/j.vaccine.2008.07.057","volume":"26","author":"IS Lukashevich","year":"2008","unstructured":"Lukashevich, I. S. et al. Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. Vaccine 26, 5246\u20135254 (2008).","journal-title":"Vaccine"},{"key":"1012_CR72","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/1743-422X-10-52","volume":"10","author":"JC Zapata","year":"2013","unstructured":"Zapata, J. C. et al. An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity. Virol J 10, 52 (2013).","journal-title":"Virol J"},{"key":"1012_CR73","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.cell.2015.07.020","volume":"162","author":"KG Andersen","year":"2015","unstructured":"Andersen, K. G. et al. Clinical sequencing uncovers origins and evolution of Lassa virus. Cell 162, 738\u2013750 (2015).","journal-title":"Cell"},{"key":"1012_CR74","doi-asserted-by":"publisher","first-page":"12166","DOI":"10.1128\/JVI.02075-15","volume":"89","author":"M Iwasaki","year":"2015","unstructured":"Iwasaki, M., Ngo, N., Cubitt, B., Teijaro, J. R. & de la Torre, J. C. General molecular strategy for development of arenavirus live-attenuated vaccines. J Virol 89, 12166\u201312177 (2015).","journal-title":"J Virol"},{"key":"1012_CR75","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.virol.2016.11.001","volume":"501","author":"BYH Cheng","year":"2017","unstructured":"Cheng, B. Y. H., Nogales, A., de la Torre, J. C. & Martinez-Sobrido, L. Development of live-attenuated arenavirus vaccines based on codon deoptimization of the viral glycoprotein. Virology 501, 35\u201346 (2017).","journal-title":"Virology"},{"key":"1012_CR76","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.3390\/v14112445","volume":"14","author":"NM Elemam","year":"2022","unstructured":"Elemam, N. M., Talaat, I. M. & Maghazachi, A. A. CXCL10 chemokine: a critical player in RNA and DNA viral infections. Viruses 14, 2445 (2022).","journal-title":"Viruses"},{"key":"1012_CR77","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s10020-020-00230-x","volume":"26","author":"Y Chen","year":"2020","unstructured":"Chen, Y. et al. IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19. Mol Med 26, 97 (2020).","journal-title":"Mol Med"},{"key":"1012_CR78","doi-asserted-by":"publisher","first-page":"5531","DOI":"10.4049\/jimmunol.0904091","volume":"185","author":"SC Liang","year":"2010","unstructured":"Liang, S. C. et al. IL-22 induces an acute-phase response. J Immunol 185, 5531\u20135538 (2010).","journal-title":"J Immunol"},{"key":"1012_CR79","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1146\/annurev-immunol-032414-112123","volume":"33","author":"JA Dudakov","year":"2015","unstructured":"Dudakov, J. A., Hanash, A. M. & van den Brink, M. R. M. Interleukin-22: immunobiology and pathology. Annu Rev Immunol 33, 747\u2013785 (2015).","journal-title":"Annu Rev Immunol"},{"key":"1012_CR80","doi-asserted-by":"publisher","first-page":"G827","DOI":"10.1152\/ajpgi.00513.2005","volume":"290","author":"S Brand","year":"2006","unstructured":"Brand, S. et al. IL-22 is increased in active Crohn\u2019s disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol 290, G827\u2013838, (2006).","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"1012_CR81","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-015-0335-3","volume":"12","author":"G Perriard","year":"2015","unstructured":"Perriard, G. et al. Interleukin-22 is increased in multiple sclerosis patients and targets astrocytes. J Neuroinflammation 12, 119 (2015).","journal-title":"J Neuroinflammation"},{"key":"1012_CR82","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1128\/IAI.67.5.2590-2601.1999","volume":"67","author":"A Diab","year":"1999","unstructured":"Diab, A. et al. Neutralization of macrophage inflammatory protein 2 (MIP-2) and MIP-1\u03b1 attenuates neutrophil recruitment in the central nervous system during experimental bacterial meningitis. Infect Immun 67, 2590\u20132601 (1999).","journal-title":"Infect Immun"},{"key":"1012_CR83","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1016\/j.vaccine.2024.02.044","volume":"42","author":"L Kabore","year":"2024","unstructured":"Kabore, L., Pecenka, C. & Hausdorff, W. P. Lassa fever vaccine use cases and demand: Perspectives from select West African experts. Vaccine 42, 1873\u20131877 (2024).","journal-title":"Vaccine"},{"key":"1012_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-019-0104-x","volume":"4","author":"DR Stein","year":"2019","unstructured":"Stein, D. R. et al. A recombinant vesicular stomatitis-based Lassa fever vaccine elicits rapid and long-term protection from lethal Lassa virus infection in guinea pigs. NPJ Vaccines 4, 8 (2019).","journal-title":"NPJ Vaccines"},{"key":"1012_CR85","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.antiviral.2011.02.012","volume":"90","author":"KA Cashman","year":"2011","unstructured":"Cashman, K. A. et al. Evaluation of Lassa antiviral compound ST-193 in a guinea pig model. Antiviral Res 90, 70\u201379 (2011).","journal-title":"Antiviral Res"},{"key":"1012_CR86","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1093\/bioinformatics\/btt509","volume":"29","author":"EP Nawrocki","year":"2013","unstructured":"Nawrocki, E. P. & Eddy, S. R. Infernal 1.1: 100-fold faster RNA homology searches. Bioinformatics 29, 2933\u20132935 (2013).","journal-title":"Bioinformatics"},{"key":"1012_CR87","doi-asserted-by":"publisher","DOI":"10.1093\/gigascience\/giab008","volume":"10","author":"P Danecek","year":"2021","unstructured":"Danecek, P. et al. Twelve years of SAMtools and BCFtools. Gigascience 10, giab008 (2021).","journal-title":"Gigascience"},{"key":"1012_CR88","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna, A. et al. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20, 1297\u20131303 (2010).","journal-title":"Genome Res"},{"key":"1012_CR89","doi-asserted-by":"publisher","first-page":"S635","DOI":"10.1093\/infdis\/jiad374","volume":"228","author":"SR Stein","year":"2023","unstructured":"Stein, S. R. et al. Clinical and immunologic correlates of vasodilatory shock among Ebola virus-infected nonhuman primates in a critical care model. J Infect Dis 228, S635\u2013S647 (2023).","journal-title":"J Infect Dis"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01012-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01012-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01012-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T18:02:50Z","timestamp":1732384970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01012-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,17]]},"references-count":89,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1012"],"URL":"https:\/\/doi.org\/10.1038\/s41541-024-01012-w","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,17]]},"assertion":[{"value":"29 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the original version of this article, the SI file with track changes is replaced with the clean version of the supplementary file.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"220"}}